Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Aggression × selinexor × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 23 Leukemia, Myeloid, Acute 21 Recurrence 12 Sarcoma 6 Lymphoma, Large B-Cell, Diffuse 5 Neurofibrosarcoma 4 Neoplasms, Plasma Cell 4 Neoplasm Metastasis 4 Lymphoma 4 Myelodysplastic Syndromes 3 Lymphoma, Non-Hodgkin 3 Lymphoma, B-Cell 3 Thymoma 2 Rhabdoid Tumor 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Ovarian Neoplasms 2 Neoplasms 2 Lymphoma, Mantle-Cell 2 Liposarcoma 2 Leukemia, Myelomonocytic, Chronic 2 Leukemia, Biphenotypic, Acute 2 Leukemia 2 Congenital Abnormalities 2 Carcinoma 2 Wilms Tumor 1 Waldenstrom Macroglobulinemia 1 Vascular Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solitary Fibrous Tumors 1

Interventions

selinexor 1 pegfilgrastim 1 Topotecan 1 Rituximab 1 Prednisone 1 Positron Emission Tomography Computed Tomography 1 Paclitaxel 1 Methylprednisolone 1 Immunologic Techniques 1 Ifosfamide 1 Flow Cytometry 1 Etoposide 1 Dexamethasone 1 Clofarabine 1 Carboplatin 1 Alemtuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02471911 2022-04-12

KPT-330+RICE

Weill Medical College of Cornell University

Phase 1 Completed

Aggression, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡